Navigation Links
Neuroscientist from Tufts School of Medicine named NIH New Innovator
Date:9/24/2009

BOSTON (September 24, 2009) Leon Reijmers, PhD, assistant professor of neuroscience at Tufts University School of Medicine in Boston, is one of 55 recipients of the National Institutes of Health Director's New Innovator Award. Reijmers is investigating the way memories are stored in the brain, specifically focusing on the proteins involved in long-term memory storage.

Groups of neurons that participate in long-term memory storage are called memory traces. Memory traces are formed when neurons make new connections with other neurons, a process that requires the production of proteins. Little is known about the specific proteins involved in forming memory traces. Reijmers is working to identify these proteins, which will provide much-needed information about how memories are stored in the brain.

"In many ways, the synaptic mechanisms behind the storage of memories are a mystery. Once we isolate the specific proteins needed to establish memory traces, we will be better equipped to develop new approaches for treating diseases that cause memory loss, such as Alzheimer's disease," said Reijmers.

In earlier research, Reijmers helped develop a transgenic mouse model that allows researchers to locate the neurons involved in the storage of memories. Reijmers' current research uses the model to extract the messenger RNA, or protein blueprints, that dictate which proteins are produced during the storage of a new memory. Additionally, the messenger RNA will be analyzed at different times to see how the proteins involved in the storage of new memories compare to the proteins involved in the maintenance of memories.

"The research methods we are pioneering at Tufts will help us understand the mechanisms of memory and, once refined, can be applied to the study of addiction, epilepsy, circadian rhythms, spinal cord regeneration, pain, brain development, and neuronal cell death," said Reijmers.

"The neuroscience department at Tufts is known for its research into cellular and molecular neuroscience with a particular focus on synapse neurobiology and neurogenetics. Dr. Reijmers' work in memory adds to this depth and promises to contribute to the breakthroughs that will create new areas of therapeutics," said Michael Rosenblatt, MD, dean of Tufts University School of Medicine. "We are honored that NIH has identified his work as having the potential to accelerate the research that will yield benefits to health."

Reijmers, a new addition to the faculty at Tufts School of Medicine, will also be working with members of the neuroscience program at the Sackler School of Graduate Biomedical Sciences at Tufts.

The NIH Director's New Innovator Award is supported by the NIH Common Fund's Roadmap for Medical Research, with additional funding from the American Recovery and Reinvestment Act. The New Innovator Award supports early-career scientists who take innovative approaches to major challenges in biomedical research. This prestigious award totals $1.5 million over five years.


'/>"/>

Contact: Siobhan Gallagher
617-636-6586
Tufts University, Health Sciences
Source:Eurekalert

Related medicine news :

1. Brandeis neuroscientist wins NIH directors Pioneer Award
2. Jefferson neuroscientists show anti-inflammation molecule helps fight MS-like disease
3. Leading neuroscientist seeks beauty, love and happiness
4. Carnegie Mellon neuroscientist proposes new theory of brain flexibility
5. Jefferson neuroscientists find early lead exposure impedes recovery from brain injury
6. MITs McGovern Institute honors Emory neuroscientist for contributions to psychiatry
7. Aussie neuroscientist tests addiction drug
8. Chicago neuroscientist contributes to book on brains and baseball
9. Kavli Prize awarded to Pasko Rakic, pioneering Yale neuroscientist
10. QBI neuroscientists make Alzheimers disease advance
11. Neuroscientists show insulin receptor signaling regulates structure of brain circuits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 2016 , ... The medical profession is well aware that heart attacks do ... analyzing heart attacks among 138,602 people recorded a 35% higher number of heart attacks ... agree of course–no time of year is a good time for a heart attack! ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 2016 BOC Business Brilliance Awards under the Best New Product Launch category. Gensuite’s ... achieved through user experience. , BOC Global Events & Training Group is a ...
(Date:12/7/2016)... ... December 07, 2016 , ... Maureen McLaughlin, LA.c., a certified ... Associates of Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with fertility ... patients realize their family building goals. Acupuncture helps fertility patients by ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a brief ... the presidency and to America. “Tomorrow Trump Goes To Washington” is the creation of ... can for this country. , Nancy attributes her patriotic nature to her WWII veteran ...
(Date:12/7/2016)... ... ... “Fred Rides a Train” allows readers to tag along on a special ... Train” is the creation of published author, Janet Morrison, who has been writing mostly ... "Fred, the Dog" series is her first attempt at writing for children. Janet, Fred, ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Inc. (NASDAQ: IONS ), the leader in antisense therapeutics, ... BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, December ... A live webcast of the presentation will be available on the ... be available within 48 hours and will be archived for a ... , , ...
(Date:12/7/2016)... PHILADELPHIA , Dec. 7, 2016  Lannett Company, Inc. (NYSE: ... at the BMO Capital Markets 2016 Prescription for Success Healthcare Conference ... Barclay hotel in New York City . ... investors participating at the Guggenheim Securities 4 th Annual Boston ... Boston hotel. ...
(Date:12/6/2016)... 2016  Alopexx Oncology, LLC announced data from a ... protein (immunocytokine) composed of interleukin-2 and a CD20-targeting monoclonal ... B cells as Rituxan and maintains the activities of ... involved in tumor targeting, engagement of the immune system, ... of the study (abstract #95954) were presented at the ...
Breaking Medicine Technology: